Combination Principles - Why More is More
- Maximize Efficacy: Achieve synergistic cytotoxicity ($1+1>2$) by targeting different molecular pathways and cell cycle phases.
- Broaden Coverage: Effective against heterogeneous cancer cell populations, including both rapidly dividing and quiescent cells.
- Prevent/Overcome Resistance: Reduces the probability of resistant clones emerging by attacking the cancer from multiple angles.
- Minimize Toxicity: Combine drugs with non-overlapping dose-limiting toxicities (e.g., avoid combining two drugs that both cause severe bone marrow suppression).
⭐ The MOPP regimen (Mechlorethamine, Oncovin, Procarbazine, Prednisone) for Hodgkin lymphoma was one of the first successful combination therapies, dramatically improving cure rates from <10% to >70%.
📌 Many regimens are acronyms, e.g., R-CHOP for lymphoma: Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone.
Heme Malignancy Regimens - Alphabet Soup Assault
📌 Mnemonic: Key drugs are often represented by their first letter in the regimen acronym.
| Malignancy | Regimen | Key Components |
|---|---|---|
| Hodgkin Lymphoma | ABVD | Adriamycin (Doxorubicin), Bleomycin, Vinblastine, Dacarbazine |
| Non-Hodgkin (DLBCL) | R-CHOP | Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone |
| CLL/SLL | FCR | Fludarabine, Cyclophosphamide, Rituximab |
| AML | 7 + 3 | Cytarabine (for 7 days) + Idarubicin/Daunorubicin (for 3 days) |
| Multiple Myeloma | VRd | Velcade (Bortezomib), Revlimid (Lenalidomide), dexamethasone |
Solid Tumor Regimens - Targeted Cocktail Party
| Regimen Combination | Target(s) & Synergy | Key Indication(s) |
|---|---|---|
| Dabrafenib + Trametinib | BRAF V600E + MEK; Vertical pathway blockade | Metastatic Melanoma |
| Trastuzumab + Pertuzumab | HER2 (dual blockade); Prevents dimerization | HER2+ Breast Cancer |
| Ipilimumab + Nivolumab | CTLA-4 + PD-1; Synergistic immune activation | Melanoma, RCC, NSCLC |
| Atezolizumab + Bevacizumab | PD-L1 + VEGF; Enhances T-cell tumor infiltration | Hepatocellular Carcinoma, NSCLC |
| Pembrolizumab + Lenvatinib | PD-1 + Multi-kinase (VEGFR); Immune + anti-angiogenic | Endometrial Ca, RCC |
Toxicity & Rescue - The Damage Control
| Drug / Toxin | Specific Toxicity | Rescue Agent / Management |
|---|---|---|
| Methotrexate | Myelosuppression, Mucositis | Leucovorin (Folinic Acid) "rescue" |
| Cisplatin | Nephrotoxicity, Ototoxicity | Amifostine, Chloride Diuresis |
| Doxorubicin | Dilated Cardiomyopathy | Dexrazoxane (Iron Chelator) |
| Cyclophosphamide | Hemorrhagic Cystitis (Acrolein) | Mesna, Aggressive Hydration |
| Bleomycin | Pulmonary Fibrosis, Skin changes | Monitor PFTs, Corticosteroids |
| Vinca Alkaloids | Peripheral Neuropathy (dose-limiting) | Dose modification/discontinuation |
High‑Yield Points - ⚡ Biggest Takeaways
- Combination chemotherapy regimens like ABVD or R-CHOP are standard to maximize efficacy and prevent drug resistance.
- Drugs are selected to have synergistic effects by targeting different cellular mechanisms or cell cycle phases.
- A key principle is combining agents with non-overlapping toxicities to improve patient tolerance and allow for higher doses.
- Leucovorin is used for "rescue" with high-dose methotrexate but potentiates 5-FU's cytotoxicity.
- Always monitor for cumulative, dose-limiting toxicities like doxorubicin cardiotoxicity or bleomycin pulmonary fibrosis.
Unlock the full lesson and continue reading
Signup to continue reading this lesson and unlimited access questions, flashcards, AI notes, and more
